The new facility offers an expanded laboratory alongside meeting areas dedicated to development meetings, formulation workshops, and brainstorming sessions
New site expands manufacturing footprint to meet future demand; ensures continued on-time delivery rate of >99.9% to patients across western US, Alaska and Hawaii
Facility also named 2025 ISPE Facility of the Year Winner for Social Impact - Unmet Medical Needs
Aim is to predict novel catalysts using machine learning (ML) and artificial intelligence (AI) techniques
The San Francisco facility is part of Thermo Fisher’s global pharma services network of more than 15 locations supporting cell and gene therapies.
The strategic acquirer maintains a nationwide presence in the LTC pharmacy space
The 41,000 sq ft facility will be utilized to manufacture clinical to commercial-grade peptide products for increased manufacturing capacity
Formycon AG will develop, register, manufacture and supply the product, while Zydus Lifesciences Global FZE, United Arab Emirates will be responsible for the commercialization of FYB206 in the defined territories
The collaboration to develop breakthrough myeloid cell engagers (MCEs) signals a bold push into a promising new frontier in cancer therapy
Novartis is the only pharmaceutical company with a dedicated commercial RLT portfolio
Subscribe To Our Newsletter & Stay Updated
